The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
The anti‐amnesic and neuroprotective effects of donepezil against amyloid β25‐35peptide‐induced toxicity in mice involve an interaction with the σ1receptor
Open accessAbstract
Background and purpose: The acetylcholinesterase inhibitor, donepezil, is also a high affinity σ 1 receptor agonist. We examined the involvement of σ 1 receptors in its anti‐amnesic and neuroprotective properties against amyloid β 25‐35 peptide‐induced toxicity in mice. Experimental approach: Mice were given an intracerebroventricular (i.c.v.) injection of Aβ 25‐35 peptide (9 nmol) 7‐9 days before being tested for spontaneous alternation and passive avoidance. Hippocampal lipid peroxidation was measured 7 days after Aβ 25‐35 injection to evaluate oxidative stress. Donepezil, the σ 1 agonist PRE‐084 or the cholinesterase (ChE) inhibitors tacrine, rivastigmine and galantamine were administered either 20 min before behavioural sessions to check their anti‐amnesic effects, or 20 min before Aβ 25‐35 injection, or 24 h after Aβ 25‐35 injection and then once daily before behavioural sessions, to check their pre‐ and post‐i.c.v. neuroprotective activity, respectively. Key results: All the drugs tested were anti‐amnesic, but only the effects of PRE‐084 and donepezil were prevented by the σ 1 antagonist BD1047. Only PRE‐084 and donepezil showed neuroprotection when administered pre i.c.v.; they blocked lipid peroxidation and learning deficits, effects inhibited by BD1047. Post i.c.v., PRE‐084 and donepezil showed complete neuroprotection whereas the other ChE inhibitors showed partial effects. BD1047 blocked these effects of PRE‐084, attenuated those of donepezil, but did not affect the partial effects of the other ChE inhibitors. Conclusions and implications.: The potent anti‐amnesic and neuroprotective effects of donepezil against Aβ 25‐35‐induced toxicity involve both its cholinergic and σ 1 agonistic properties. This dual action may explain its sustained activity compared to other ChE inhibitors. British Journal of Pharmacology(2006)149, 998–1012. doi:10.1038/sj.bjp.0706927
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ghribi, O., Herman, M. M., Pramoonjago, P., Spaulding, N. K., & Savory, J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.002 · Cited by 31
RetractedFunctional rafts in cell membranes
Simons, K., & Ikonen, E. (1997) · Nature · doi:10.1038/42408 · Cited by 9,757
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“The truncated Ab25–35 fragment includes extracellular and transmembrane residues that have been reported to represent an active region of Ab (Yankner et al., 1990).”
BackgroundMattson, M., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00376.1992 · Cited by 1,627
PHARMACOLOGICAL EFFECTS PRODUCED BY INTRACEREBRAL INJECTION OF DRUGS IN THE CONSCIOUS MOUSE
HALEY, T. J., & McCORMICK, W. G. (1957) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1957.tb01354.x · Cited by 1,526
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417
In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity
Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991) · Brain Research · doi:10.1016/0006-8993(91)91553-d · Cited by 828
Cited by
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
The pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654
Self-citationNew insights into brain BDNF function in normal aging and Alzheimer disease
Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 571
The sigma-1 receptor chaperone as an inter-organelle signaling modulator
Su, T.-P., Hayashi, T., Maurice, T., Buch, S., & Ruoho, A. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.007 · Cited by 466
Self-citationThe Infectious Etiology of Alzheimer’s Disease
Sochocka, M., Zwolińska, K., & Leszek, J. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170313122937 · Cited by 399
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
“[145] developed tacrine analogues bearing a racemic 9,10,11,12tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amine heterocyclic structure with a differently substituted benzene ring at position 7 (Fig.”
BackgroundProtective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats
Arancibia, S., Silhol, M., Moulière, F., Meffre, J., Höllinger, I., Maurice, T., & Tapia-Arancibia, L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.012 · Cited by 317
Self-citationBuckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 308
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
The Possibility of an Infectious Etiology of Alzheimer Disease
Ashraf, G. M., Tarasov, V. V., Makhmutovа, A., Chubarev, V. N., Avila-Rodriguez, M., Bachurin, S. O., & Aliev, G. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1388-y · Cited by 175
Ueda, A., Shinkai, S., Shiroma, H., Taniguchi, Y., Tsuchida, S., Kariya, T., Kawahara, T., Kobayashi, Y., Kohda, N., Ushida, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100398 · Cited by 155
Villard, V., Espallergues, J., Keller, E., Vamvakides, A., & Maurice, T. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379286 · Cited by 139
Self-citationWu, C.-R., Lin, H.-C., & Su, M.-H. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-202 · Cited by 85
“Donepezil, a selective AChE inhibitor, possess neuroprotective activity against Aβinduced toxicity in vitro and in vivo [19,20].”
BackgroundResultInfluentialThe Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory
Wigmore, P. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_235 · Cited by 66
Shehata, M. K., Ismail, A. A., & Kamel, M. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417928 · Cited by 55
Scheiner, M., Dolles, D., Gunesch, S., Hoffmann, M., Nabissi, M., Marinelli, O., Naldi, M., Bartolini, M., Petralla, S., Poeta, E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00623 · Cited by 49
Self-citationAZP2006, a new promising treatment for Alzheimer’s and related diseases
Callizot, N., Estrella, C., Burlet, S., Henriques, A., Brantis, C., Barrier, M., Campanari, M. L., & Verwaerde, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-94708-1 · Cited by 35
Mutational Analysis of Sigma-1 Receptor’s Role in Synaptic Stability
Ryskamp, D. A., Zhemkov, V., & Bezprozvanny, I. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01012 · Cited by 21
Metadata
- Authors
- Meunier, J., Ieni, J., & Maurice, T.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-12
- Volume
- 149
- Issue
- 8
- Pages
- 998-1012
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1500642137
- Cited by
- 288
- References
- 70
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.